A felodipine-metoprolol extended-release tablet: its properties and clinical development

Abstract

The current failure of antihypertensive therapy to control BP in many hypertensive patients highlights the need for new treatment strategies. Ideally, these new strategies should provide reliable, effective 24 h BP control in all types of patients with a convenient, well-tolerated regimen. Logimax, an extended-release tablet containing felodipine and metoprolol, has been developed, which provides more effective control of BP in a wider range of patients than either component as monotherapy, without compromising tolerability. This combination increases the likelihood of achieving target BP and is therefore likely to provide further reductions in cardiovascular risk.